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Formins stimulate actin filament assembly for funda-
mental cellular processes including division, adhe-
sion, establishing polarity, and motility. A formin
inhibitor would be useful because most cells express
multiple formins whose functions are not known and
because metastatic tumor formation depends on the
deregulation of formin-dependent processes. We
identified a general small molecule inhibitor of formin
homology 2 domains (SMIFH2) by screening com-
pounds for the ability to prevent formin-mediated
actin assembly in vitro. SMIFH2 targets formins from
evolutionarily diverse organisms including yeast,
nematode worm, and mice, with a half-maximal
inhibitor concentration of 5 to 15 mM. SMIFH2 pre-
vents both formin nucleation and processive barbed
end elongation and decreases formin’s affinity for the
barbed end. Furthermore, low micromolar concen-
trations of SMIFH2 disrupt formin-dependent, but
not Arp2/3 complex-dependent, actin cytoskeletal
structures in fission yeast and mammalian NIH 3T3
fibroblasts.
INTRODUCTION
Cells assemble diverse actin-dependent structures for a variety
of fundamental processes, each of which is thought to be reliant
on specific actin nucleation factors such as the Arp2/3 complex,
Spire, and formin (Chhabra and Higgs, 2007). Determining which
factors drive actin filament assembly for particular cellular func-
tions is daunting. Formins are evolutionarily conserved proteins
that stimulate actin assembly for a variety of processes including
division, motility, establishing polarity, stress fiber formation,
focal adhesions, and cell-to-cell adhesions (Faix and Grosse,
2006; Goode and Eck, 2007; Higgs, 2005), which are often
deregulated during tumor cell transformation and metastasis
(Sahai, 2005). Not surprising then, formins are involved in malig-1158 Chemistry & Biology 16, 1158–1168, November 25, 2009 ª200nant tumor function and are highly overexpressed in different
cancer cell types including colorectal, carcinoma, leukemia,
melanoma, and lymphoid (Favaro et al., 2003; Kitzing et al.,
2007; Sarmiento et al., 2008; Zhu et al., 2008). Determining for-
min’s numerous roles is particularly complicated because most
organisms express multiple isoforms (Goode and Eck, 2007).
For example, there are at least 20 formin genes in plants, 18 in
mammals, 6 each in Drosophila melanogaster andCaenorhabdi-
tis elegans, 3 in fission yeast, and 2 in budding yeast (Higgs,
2005). A major challenge is to elucidate all formin-dependent
cellular functions in both healthy and diseased tissues.
Formins are multidomain proteins that contain a highly
conserved actin assembly formin homology 2 FH2 domain and
its associated profilin-binding FH1 domain, which are flanked
on either side by regulatory domains that coordinate localization
and activation (Goode and Eck, 2007; Higgs, 2005). Some for-
mins are autoinhibited by association of their N- and C-terminal
regulatory domains and activated by GTP-bound small Rho-
GTPases (Goode and Eck, 2007; Wallar and Alberts, 2003).
Upon activation, the FH2 domain either nucleates actin filament
assembly or associates with preexisting filaments and remains
continuously associated with the elongating actin filament
barbed end (Higashida et al., 2004; Kovar and Pollard, 2004).
Processive association allows formins to protect barbed ends
from capping proteins (Harris et al., 2004; Kovar et al., 2005;
Moseley et al., 2004; Zigmond et al., 2003) and to stimulate the
addition of FH1 domain-bound profilin-actin (Kovar et al.,
2006; Kovar and Pollard, 2004; Neidt et al., 2008; Paul and
Pollard, 2008; Romero et al., 2004; Vavylonis et al., 2006). As
a result, formins produce long-straight filaments that are often
bundled in cells and pulled by myosin motors to produce con-
tractile forces, such as the cytokinetic contractile ring and stress
fibers (Glotzer, 2005; Naumanen et al., 2008).
Given that the roles of most formins in different cell types are
not known, and the potential for formin as an anti-cancer target,
inhibitors of formin-mediated actin assembly would be extremely
useful. We report here a simple fluorescence-based in vitro
screen and identification of the first general small molecule inhib-
itor of formin-mediated actin assembly that disrupts formin-
dependent processes from yeast to mammals.9 Elsevier Ltd All rights reserved
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Figure 1. Structure and Activity of SMIFH2 Analog Molecules
(A) Structure of SMIFH2 (1) and analog molecules 2–7.
(B) Plot of the dependence of the assembly rate of 2.5 mM Mg-ATP actin monomers (20% pyrene-labeled) in the presence of 25 nM mouse formin mDia1 on the
concentration of SMIFH2 (1) (C) and analog molecules 2 (A), 3 (B), 4 (O), 5 (,), 6 (>), and 7 (-). Conditions were the same as in Figure 2.
(C) Fission yeast cells expressing either GFP-CHD (top panels) to label the entire actin cytoskeleton or type V myosin Myo52-GFP (bottom panels), following treat-
ment for 30 min at 25C with 10 mM of the indicated analog. Numbers in the left corner of lower panels represent the percentage of cells in which Myo52-GFP is
localized specifically to cell tips via formin-dependent actin cables.RESULTS AND DISCUSSION
Identification of a Small Molecule that Inhibits
Formin-Mediated Actin Assembly
We screened 10,000 commercially available small molecules
(ChemBridge) for the ability to prevent mouse formins
mDia1(FH1FH2) and mDia2(FH1FH2) from stimulating actin
assembly in vitro (see Experimental Procedures). We identified
a compound that we named SMIFH2 for small molecule inhibitor
of formin FH2 domain-mediated actin assembly (see Figure 1A).
This 2-thiooxodihydropyrimidine-4,6-dione derivative inhibits
mouse formin mDia1(FH1FH2)-mediated assembly of profilin-
actin in a concentration-dependent manner (Figures 2A and
2B). Half-maximal inhibition occurs at 15.0 mM SMIFH2, and
at saturating concentrations of SMIFH2 the rate of assembly
is identical to the rate without formin. Control experiments
demonstrate that SMIFH2 is specific for formin-mediated actin
assembly. High concentrations of SMIFH2 did not eliminate the
spontaneous assembly of actin monomers without formin
(Figure 2C), the addition of actin to the barbed end of preassem-
bled filaments without formin (Figures 2G and 2I; see Figures
S1C and S1E available online), or actin polymerization stimulated
with Arp2/3 complex (Figures 2E and2F).
With similar potency SMIFH2 also inhibits mDia1(FH1FH2)
without profilin, as well as the construct mDia1(FH2) lacking
the profilin binding FH1 domain (Figure 2B). Thus, the molecular
target of SMIFH2 is likely the highly conserved FH2 domain.
SMIFH2 also inhibits actin assembly by evolutionarily diverse
formin FH1FH2 constructs including C. elegans CYK-1,
S. pombe Cdc12, S. pombe Fus1, S. cerevisiae Bni1, and
M. musculus mDia2 (Figures 2B and 2C). Therefore, SMIFH2Chemistry & Biology 16, 1158–11is a general inhibitor of actin assembly mediated by formin
FH2 domains.
SMIFH2 Inhibits Both Formin-Mediated Nucleation
and Elongation
Formins nucleate actin assembly and drive rapid elongation of
profilin-actin by remaining continually associated with the elon-
gating barbed end (Kovar, 2006). We determined that SMIFH2
inhibits formin-mediated nucleation by visualizing the products
of spontaneous assembly reactions upon reaching plateau
(Figure 2D). Filament length is proportional to the number of fila-
ments. Control reactions without formin produce long fila-
ments (21 mm) compared to reactions with formins (1.5 and
0.5 mm for mouse mDia2 and fission yeast Cdc12, respec-
tively). SMIFH2 inhibits formin nucleation, resulting in filament
lengths similar to controls without formin (18 and 21 mm for
mDia2 and Cdc12, respectively).
We determined that SMIFH2 inhibits formin-mediated elonga-
tion by measuring the addition of profilin-actin to preassembled
formin-associated filaments (Figures 2G–2J). In the absence of
SMIFH2, formin-associated filaments rapidly assemble upon
addition of profilin-actin. Conversely, SMIFH2 severely blocked
the elongation of both Cdc12- and mDia2-associated filaments.
Half-maximal inhibition occurs at 4.0 mM SMIFH2 (Figure 2J).
SMIFH2 did not inhibit the barbed end elongation of filaments
without formin (Figures 2G and 2I).
SMIFH2 Decreases the Affinity of Formin for the Actin
Filament Barbed End
We determined that SMIFH2 decreases the affinity of formin
for the barbed end by three assays. First, high concentrations68, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1159
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Figure 2. SMIFH2 Inhibits Formin-Mediated
Actin Assembly In Vitro
(A) Time course of the polymerization of 2.5 mM Mg-
ATP actin monomers (20% pyrene-labeled) with
2.5 mM profilin MmPRF1 in either the absence (thick
curve) or presence of 25 nM mDia1(FH1FH2) and 0.0
(-), 7.5 (C), 10 (A), or 100 (:) mMSMIFH2. Conditions:
10 mM imidazole (pH 7.0), 50 mM KCl, 1 mM MgCl2, 1
mMEGTA, 0.5mMDTT, 0.2mMATP,and90mMCaCl2.
(B)Plot of thedependenceof themaximumpolymeriza-
tion rateof 2.5mMMg-ATPactinon theconcentrationof
SMIFH2 in the presence of the indicated formin
constructs.
(C) Bar graph of the effect of 50 mM SMIFH2 on the
maximumpolymerization rate of 2.5 mMactinmonomer
in the absence (No Formin) or presence of diverse for-
min (FH1FH2) constructs: 25 nM mouse mDia1,
25 nM mouse mDia2, 100 nM nematode worm CYK-
1, 100 nM fission yeast Cdc12, 10 nM fission yeast
Fus1, and 75 nM budding yeast Bni1. Error bars, SD;
n = 3.
(D) Fluorescent micrographs of the products of actin
polymerization assays from (C) stained with rhoda-
mine-phalloidin. Bar, 1.0 mm.
(E and F) Effect of 100 mM SMIFH2 or Arp2/3 complex
inhibitors CK-666 and CK-869 (Nolen et al., 2009) on
the polymerization of 2.5 mM actin monomers with
25 nM Arp2/3 complex and 100 nM GST-WASP-VCA.
Error bars, SD; n = 3.
(G–J) Effect of SMIFH2 on the elongation of filaments
preassembled by formin. Unlabeled actin (2.5 mM)
was preassembled alone or in the presence of 50 nM
Cdc12(FH1FH2) or mDia2(FH1FH2), treated with a
range of concentrations of SMIFH2 and diluted 15-fold into new reactions with 0.5 mMMg-ATP-actin (10% pyrene-labeled) and 5.0 mM profilin.
(G) Time course of the elongation of control filaments preassembled without formin in the absence (B) or presence (C) of 10 mM SMIFH2.
(H) Time course of the elongation of Cdc12-assembled filaments alone (C), with profilin (-), and with profilin and 10 mM SMIFH2 (A).
(I) Bar graph of the effect of 10 mM SMIFH2 on the maximum elongation rate of control and formin-assembled filaments. Error bars, SD; n = 3.
(J) Plot of the dependence of the polymerization rate on the concentration of SMIFH2 for filaments preassembled by formin.of SMIFH2 allow barbed ends to depolymerize in the presence
of formin (Figures S1A and S1B). In the absence of SMIFH2,
formin significantly inhibits the depolymerization of preassem-
bled filaments upon dilution below the barbed end critical
concentration. Concentrations of SMIFH2 above 25 to 50 mM
allow rapid barbed end depolymerization in the presence
of both Cdc12 and mDia2. Conversely, SMIFH2 had no effect
on the barbed end depolymerization rate without formin (Fig-
ure S1B).
Second, we determined the effect of SMIFH2 on the ability of
formin to bind to the barbed end and reduce the rate of monomer
addition (Figures S1C–S1E). Cdc12 binds to preassembled
barbed ends and severely inhibits their elongation in the absence
of profilin (Figures S1D and S1E) (Kovar et al., 2003). In a con-
centration-dependent manner, SMIFH2 prevents Cdc12 from
binding to the barbed end, allowing filaments to elongate near
the control rate (Figures S1D and S1E). Conversely, SMIFH2
had no effect on the rate of barbed end elongation in the absence
of formin (Figures S1C and S1E).
Third, we determined that SMIFH2 does not allow formin to
inhibit the end-to-end annealing of actin filaments (Figure S2).
Formin-associated filaments do not anneal (Kovar et al., 2003).
SMIFH2 allowed preassembled filaments severed in the pres-
ence of Cdc12 to anneal (Figures S2A and S2B) and allowed
Cdc12- and mDia2-nucleated filament seeds to anneal (Figures1160 Chemistry & Biology 16, 1158–1168, November 25, 2009 ª200S2C and S2D). Conversely, SMIFH2 had no effect on annealing
in the absence of formin (Figures S2A and S2B).
Direct Observation of Formin Inhibition by Total Internal
Reflection Fluorescence (TIRF) Microscopy
To verify that SMIFH2 specifically inhibits formin-mediated actin
assembly, we used TIRF microscopy to observe individual fila-
ments assembled from formin in solution (Figure 3) or from for-
min immobilized on beads (Figure 4). When 1.5 mMMg-ATP actin
monomers (33% labeled with Oregon green for visualization) are
assembled in the presence of 5.0 nM mDia1(FH1FH2) and
2.5 mM profilin, two filament populations are present that differ
by both elongation rate and brightness (Figure 3A) (Kovar
et al., 2006). The first population consists of ‘‘bright’’ control fila-
ments whose barbed ends are not associated with formin and
elongate at 14 subunits/second (sub/s) (Figures 3A and 3B).
The second population consists of ‘‘dim’’ formin-associated fila-
ments that elongate their barbed ends significantly faster at
60 sub/s. 450 s after the reaction was initiated, just over 80%
of the filaments were associated with formin (Figure 3G).
In reactions containing 100 mM SMIFH2, control filaments
were unaffected, whereas the average number of dim formin-
associated filaments was significantly reduced to 10% of the
total filament population (Figures 3C–3D and 3G). The few
formin-associated filaments present in reactions containing9 Elsevier Ltd All rights reserved
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Figure 3. Evanescent Wave Fluorescent
Microscopy of the Effect of SMIFH2 on
Spontaneous Actin Assembly
Assembly of 1.0 mMATP-actin with 0.5 mMOregon
green-labeled ATP-actin in the presence of 5.0 nM
mDia1 and 2.5 mMMmPRF1 on slides coated with
NEM-myosin II. Conditions: 10 mM imidazole
(pH 7.0), 50 mM KCl, 1 mM MgCl2, 1 mM EGTA,
50 mM DTT, 0.2 mM ATP, 50 mM CaCl2, 15 mM
glucose, 20 mg/ml catalase, 100 mg/ml glucose
oxidase, 0.5% (500 centipoise) methylcellulose,
and 1.7% DMSO at 25C. Bar, 5 mm. Movies of
time lapses are published as supplemental data.
(A, C, and E) Time-lapse micrographs of represen-
tative 453 45 mm areas, with time in seconds indi-
cated at the bottom. Labels indicate control (c) and
formin-associated (f) filaments.
(B, D, and F) Plots of the length of six individual
filaments versus time for control (solid lines) and
formin-associated filaments (dashed lines). The
averagebarbedendelongation rates are indicated.
(A and B) Control reaction without SMIFH2.
(C and D) Reaction with 100 mM SMIFH2.
(E and F) Reaction with 100 mM Analog 2.
(G) Bar graph of the average percentage of formin-nucleated filaments that appear by 450 s in the entire 1333 133 mm field in both the absence and presence of
either 100 mM SMIFH2 or 100 mM Analog 2. Error bars, SD; n = 3.
(H) Dependence of the percentage of formin-nucleated filaments on the concentration of SMIFH2.100 mM SMIFH2 elongate their barbed ends at the same rate as
formin-associated filaments in control reactions without SMIFH2
(Figure 3D; 60 sub/s), suggesting that SMIFH2 inhibits formin-
mediated actin assembly by targeting formin not actin. A plot of
the dependence of the percentage of formin-nucleated filaments
on the concentration of SMIFH2 revealed half-maximal inhibition
at 25 mM SMIFH2 (Figure 3H).
When 1.5 mM Mg-ATP actin monomers (33% labeled with
Oregon green) and 7.5 mM profilin is flowed into a chamber con-
taining 2.0 mm carboxylate beads preabsorbed with GST-
mDia1(FH1FH2), actin filaments are nucleated from and remain
processively associated with formin immobilized on the beads
(Figure 4A) (Michelot et al., 2007; Romero et al., 2004). Each
formin-absorbed bead averaged slightlymore than four filaments
by 375 s (Figure 4E), which elongated at a rate of40 sub/s (Fig-
ure 4B). Filaments processively associated with mDia1 elongate
their barbed ends 33% slower in the presence of 7.5 mM profilin
than in the presence of 2.5 mMprofilin (Figures 3B and 4B) (Kovar
et al., 2006). When incubated with 100 mM SMIFH2 each formin-
absorbed bead averaged less than 0.05 filaments (Figures 4C
and 4E), which elongated at 44 sub/s (Figure 4D). A plot of the
dependence of the average number of filaments per bead
on the concentration of SMIFH2 revealed half-maximal inhibition
at 15 mM SMIFH2 (Figure 4F).
Although formin is likely the molecular target, it is theoretically
possible that SMIFH2 binds to actin in a manner that inhibits
formin-mediated assembly but not (1) spontaneous actin
assembly without formin (Figure 2C), (2) barbed end elongation
without formin (Figures 2G and 2I and Figures S1C and S1E),
(3) barbed end depolymerization without formin (Figure S1B),
and (4) Arp2/3 complex-mediated actin assembly (Figures 2E
and 2F). To establish that the molecular target of SMIFH2 is for-
min, we tested the effect of washing out SMIFH2 from formin-
associated beads before the addition of actin monomers (Fig-Chemistry & Biology 16, 1158–1ures 4G and 4H). In this case, formin-associated beads, but
not actin, are exclusively treated with SMIFH2. We found that
extensively washing beads one and fiveminutes before the addi-
tion of actin monomers only partly recovered the nucleation
activity of formin-associated beads to 0.5 and 1.25 filaments
per bead (Figure 4G). Increased nucleation activity after five
minutes likely reflects the dissociation rate of SMIFH2 from
formin.
Inhibition of the Fission Yeast Formin-Dependent Actin
Cytoskeleton
We examined the effect of SMIFH2 on fission yeast to determine
whether the compound inhibits formin-mediated processes in
cells. Fission yeast assembles four distinct filamentous actin
structures that depend on different actin nucleation factors
(Figure 5A) (La Carbona et al., 2006; Marks and Hyams, 1985).
The Arp2/3 complex is required for endocytic actin patches at
sites of polarized growth (Balasubramanian et al., 1996; McCol-
lum et al., 1996). Three formin isoforms are specifically required
for polarized actin cables (For3p; Feierbach and Chang, 2001;
Nakano et al., 2002), the cytokinetic contractile ring (Cdc12p;
Chang et al., 1997), and the mating projection tip (Fus1p;
Petersen et al., 1998). We imaged fission yeast cells expressing
GFP-CHD (actin binding domain of Rng2) to label the entire fila-
mentous actin cytoskeleton (Figure 5A) (Martin and Chang,
2006). An asynchronous population of control cells treated with
DMSO contained Arp2/3 complex-dependent patches as well
as formin-dependent actin cables and contractile rings. The
non-specific actin depolymerizing drug LatA completely disas-
sembled all filamentous actin structures (Figure 5A). The Arp2/3
complex inhibitor CK-666 specifically disassembled Arp2/3
complex-dependent actin patches (Figure 5A) (Nolen et al.,
2009). In contrast, 25 mM SMIFH2 disassembled formin-
dependent actin cables and contractile rings, but not actin168, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1161
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Figure 4. Evanescent Wave Fluorescent
Microscopy of the Effect of SMIFH2 on
Formin-Mediated Actin Assembly From
Beads
Assembly of 1.0 mMATP-actin with 0.5 mMOregon
green-labeled ATP-actin on beads coated with
GST-mDia1(FH1FH2) in the presence of 7.5 mM
MmPRF1. Conditionswere the same as in Figure 3.
Movies of time lapses shown in (A) and (C) are
published as Supplemental Data.
(A and C) Time-lapse micrographs of representa-
tive areas containing three beads (circled), with
time in seconds indicated at the bottom. Numbers
indicate individual actin filaments assembled from
each bead. Bar, 5 mm.
(B and D) Plots of the growth of six individual fila-
ment barbed ends versus time for filaments
assembled from beads. The average barbed end
elongation rate of ten filaments is indicated.
(A and B) Control reaction without SMIFH2.
(C and D) Reaction with 100 mM SMIFH2.
(E) Bar graph of the average number of filaments
per bead that appear by 375 s in both the absence
and presence of 100 mM SMIFH2. Error bars, SD;
n = 3.
(F) Dependence of the average number of fila-
ments per bead that appear by 375 s on the
concentration of SMIFH2.
(G and H) Effect of washing beads following treat-
ment with 75 mM SMIFH2.
(G) Bar graph of the average number of filaments
per bead that appear by 375 s in reactions without
SMIFH2, with SMIFH2, 1 min after SMIFH2 was
washed out, and 5 min after SMIFH2 was washed
out. Error bars, SD; n = 3.
(H) Representative regions before and after 450 s.
The number of filaments polymerized from each
bead (circled) are indicated. Bar, 5 mm.patches (Figure 5A). The concentration of SMIFH2 required to
disassemble actin cables and contractile rings varied (Figure 5B).
Whereas actin cables were lost in the presence of only 2.5 mM
SMIFH2, disassembly of contractile rings required 25 mM
SMIFH2. It is possible that contractile rings are more robust
than actin cables or that For3 is more sensitive to SMIFH2 than
is Cdc12.
To quantify the inhibitory effect of SMIFH2 on formin-
dependent actin cables and contractile rings, we imaged fission
yeast cells expressing integrated GFP fusions to proteins that
localize to particular actin structures (Figure 5C). As expected,
actin capping protein-labeled actin patches (Acp2-GFP) were
observable in 100% of cells treated with 10 mM SMIFH2.
However, the localization of GFP-tagged proteins to formin-
dependent actin cables and the contractile ring was abrogated.
Although type V myosin (Myo52-GFP) normally localizes to the
tips of interphase cells via actin cables, 10 mM SMIFH2 caused
Myo52-GFP to become distributed throughout the cell. Myo52-
GFP also distributes throughout the cell in formin For3 null cells
that completely lack actin cables (Feierbach and Chang, 2001).
Additionally, both the regulatory light chain (Rlc1-GFP) and
type II myosin (Myo2-GFP) appeared as punctate spots rather
than continuous smooth formin-dependent contractile rings at
the division site in 10 mM SMIFH2-treated cells.1162 Chemistry & Biology 16, 1158–1168, November 25, 2009 ª200Structure-Activity Relationship of SMIFH2
To gain insight into the structure-function profile of SMIFH2 (1),
we characterized the ability of six other compounds (2–7),
including both pyrimidine-2,4,6-triones and 2-thiooxodihydro-
pyrimidine-4,6-diones, to inhibit formin-mediated actin assem-
bly in vitro and disrupt the fission yeast actin cytoskeleton
(Figure 1). We found that the ability of analogs to inhibit formin-
mediated actin assembly in vitro (Figures 1B and 3E–3G) corre-
lated closely with their ability to disrupt the fission yeast formin-
dependent actin cytoskeleton (Figure 1C). None of the analogs
removed Arp2/3 complex-dependent actin patches. Analogs 2
and 3 were the most potent both in vitro and in fission yeast.
Similar to SMIFH2 (1), cells treated with 10 mM of analogs 2
and 3 for 30 min lost actin cables, resulting in mislocalization
of the type V myosin Myo52-GFP from cell tips and throughout
the cell. Analog 4 had lower potency, whereas analogs 5, 6,
and 7 had little effect on both formin-mediated actin assembly
in vitro and actin cables in fission yeast cells. Our results strongly
suggested that the thiourea moiety of SMIFH2 is an important
pharmacophoric element of this compound since a substitution
of this unit by the urea fragment resulted in substantial loss
in activity. A series of structurally related pyrimidine-2,4,6-
triones has been previously reported to inhibit cell migration by
modulating the activity of mucosal addressin cell adhesion9 Elsevier Ltd All rights reserved
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Figure 5. SMIFH2 Inhibits Formin-Mediated
Actin Assembly in Fission Yeast
(A and B) Representative micrographs demonstrate
that SMIFH2 disrupts the formin-dependent actin
cytoskeleton in fission yeast. Scale bars, 5 mm.
Fission yeast cells expressing GFP-CHD to label
the entire actin cytoskeleton: Arp2/3-dependent
actin patches, formin-dependent actin cables (small
arrows), and contractile rings (large arrowheads).
(A) Cells treated for 30min at 25Cwith either DMSO,
25 mM actin monomer binding drug Latrunculin A,
25 mM SMIFH2, or 100 mM Arp2/3 complex inhibitor
CK-666.
(B) Cells treated with a range of SMIFH2 concentra-
tions for 30 min at 25C. Top panels show actin
cables and bottom panels show contractile rings.
Cables are lost with 2.5 mM SMIFH2, whereas
contractile rings are present until 25 mM SMIFH2.
(C) Representative micrographs of fission yeast cells
expressing various GFP fusions that label specific
actin cytoskeleton structures. Cells were treated for
30 min at 25C with either DMSO or 10 mM SMIFH2.
Numbers in the top left corner indicate the per-
centage of cells containing Arp2/3 complex-depen-
dent actin capping protein patches (Acp2-GFP),
type V myosin localized to the cell tip via formin-
dependent actin cables (Myo52-GFP) (Win et al.,
2001), or normal (not punctate) localization of regula-
tory light chain (Rlc1-GFP) and type II myosin (Myo2-
GFP) to the formin-dependent contractile ring.molecule-1, with compounds 5 and 6 being the most potent in
the series (Harriman et al., 2008). Despite notable structural
homology between 5, 6, and SMIFH2 (1), there is a substantial
difference in their ability to inhibit formin-mediated actin
assembly. This data suggests that the cell-based activity of
SMIFH2 is due to selective modulation of formin and that the
activity profile is uniquely linked to the thiourea-containing struc-
ture of this compound.
SMIFH2-Induced Cytotoxicity and Growth Inhibition
of NIH 3T3 Fibroblasts
NIH 3T3 fibroblasts were incubated with a range of concentra-
tions of SMIFH2 to determine its effects on adherent mammalian
cells. Cell viability was assessed after 24 hr. SMIFH2 elicited
cytotoxicity with an IC50 of 28 mM (Figure 6A). We also observed
dose-dependent growth inhibition of NIH 3T3 fibroblasts within
a period of 96 hr (Figure 6B). In addition, cells cultured in SMIFH2
with concentrations as low as 2.5 mM were observed to have
cytokinesis defects, as measured by the percentage of multi-
nucleated cells. After 4 days, 8.6 ± 2% of cells cultured in
2.5 mM SMIFH2 had multiple nuclei as compared to 1.1 ± 0.7%
of cells treated with a DMSO control. This cytokinesis defect is
consistent with recent data showing that siRNA depletion of
mDia2 in NIH 3T3 fibroblasts increases the percentage of binu-
cleate cells to 35% (Watanabe et al., 2008).
Cellular Morphology and Protrusion Phenotypes
Observed in NIH 3T3 Fibroblasts
We took time-lapse images of NIH 3T3 fibroblasts to visualize
SMIFH2-induced phenotypes in mammalian cells. The migration
rate of cells treated with 10 mM SMIFH2 for >2 hr was reduced
two-fold compared to control cells (Figure 6C), which is consis-Chemistry & Biology 16, 1158–1tent with previous studies implicating mDia2 in cell migration
(Gupton et al., 2007). Control cells are characterized by a spread
morphology and thin sheet-like protrusions termed lamellipodia
that require Arp2/3 complex-mediated actin assembly. Over
90% of control cells have lamellipodia (Figures 6D and 6E).
Despite a less spread morphology, approximately 20% of cells
treated with less than 20 mMSMIFH2 for 6 hr still extended lamel-
lipodial protrusions (Figures 6D and 6E). Mouse formin mDia2
has been implicated in the assembly of cortical actin required
for maintaining plasma membrane integrity, and inhibition of
mDia2 led to abundant nonapoptoticmembrane blebbing (Eisen-
mann et al., 2007). Consistent with this result, we observed that
20% of cells treated with 10–20 mM SMIFH2 for 6 hr exhibit
constitutive, dynamic, small (<1 mm) blebs (Figures 6D and 6E).
At 30 mM SMIFH2, nearly all the cells exhibited large blebs
(Figures 6D and 6E), which is consistent with an IC50 of 28 mM
SMIFH2 for NIH 3T3 fibroblasts (Figure 6A). Effects of SMIFH2
perfusion were reversible on the time scale of 5 to 10 min (data
not shown).
The observed phenotype changes slowly over time when cells
are incubated with 10 mMSMIFH2 (Figure 6F). After 2 hr 60% still
retain the lamellipodial protrusive phenotype, whereas 40%
protrude by means of small dynamic blebs (Figure 6F). After
7 hr the percentage of cells exhibiting either lamellipodial protru-
sions or constitutive small blebbing decreases dramatically,
while the percentage of cells that lack protrusive activity and
appear phase dark near the cell periphery increases (Figure 6F).
Because of the static, round shape of these cells, we term this
phenotype ‘‘bulbous’’ (Figure 6D). The phase dark appearance
near the cell periphery suggests an increase in cell thickness in
this region, which may be due to decreased stability of the fila-
mentous actin cortex.168, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1163
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Figure 6. Effect of SMIFH2 on Death,
Growth, and Migration of NIH 3T3 Fibro-
blasts
(A) Cytotoxicity of SMIFH2 in 3T3 fibroblasts after
24 hr incubation, determined by measuring ATP
content as described in Experimental Procedures.
The percentages of viable cells are relative to cells
treated with DMSO only. Error bars, SD; n = 3.
(B) Inhibition of the growth of 3T3 fibroblasts by
various concentrations of SMIFH2 over 96 hr.
Cell viability was measured by ATP content and
the luminescence outputs were plotted against
incubation time. Error bars, SD; n = 3.
(C) Migration rate of NIH 3T3 fibroblasts treated
with DMSO control or 10 mM SMIFH2 for 2 and
6 hr. Error bars, SEM.
(D) Fibroblast morphologies assessed by time-
lapse phase-contrast imaging of cells treated
with SMIFH2. Lamellipodia (LP) are thin, sheet-
like protrusions in spread cells characterized by
periods of extension and retraction (indicated by
dashed line). Small Bleb phenotype is character-
ized by phase dark blebs (0.5 mm in diameter)
that extend and retract along the cell periphery in
poorly spread cells (indicated by small arrow).
Bulbous phenotype is characterized by poorly
spread cells with phase dark regions near the
periphery (arrow) and minimal protrusive activity.
Large Bleb phenotype is characterized by blebs
(>2 mm in diameter) that are static (indicated by
large arrowheads). Scale bar, 10 mm. Movies of
time lapses are published as Supplemental Data.
(E) Quantification of the percentage of fibroblasts
with the indicated cellular morphologies as a func-
tion of SMIFH2 concentration.
(F) Distribution of cellular morphologies observed
as a function of incubation time for fibroblasts
treated with 10 mM SMIFH2 (n > 100 cells for
each measurement).F-Actin Cytoskeleton in SMIFH2-Treated 3T3
Fibroblasts
We imaged filamentous actin and the focal adhesion marker
paxillin to assess the organization of the actin cytoskeleton in
cells treated with SMIFH2 (Figure 7A). In fibroblasts the actin
cytoskeleton is typically organized into prominent type II
myosin-dependent contractile bundles. The width and actin fila-
ment density of these bundles were characterized by quantifying
the variation in intensity of fluorescent phalloidin across the
bundles. ‘‘Thick’’ F-actin bundles have a mean width of 1.5 mm
and a 2.4-fold higher local actin filament density compared with
the surrounding region (Figures 7A and 7B). ‘‘Thin’’ F-actin
bundles have a mean width of 0.7 mm and a 1.5-fold enhanced
actin filament density. Interestingly, focal adhesions are similar
in cells with thick or thin F-actin bundles (Figures 7A). In control
cells, over 80% of the fibroblasts exhibited predominately thick
F-actin bundles, with only 20% exhibiting thin bundles (Fig-
ure 7C). However, 60% of cells incubated with 10 mM of SMIFH2
for 2 hr have thin F-actin bundles and only 20%have thick F-actin
bundles (Figure 7C). Moreover, approximately 5% of the spread
cells have a disorganized lamellar network and no F-actin
bundles (Figures 7A and 7C). In cells lacking F-actin bundles,
focal adhesion plaques were significantly reduced in size, remi-
niscent of nascent focal complexes that are observed to form1164 Chemistry & Biology 16, 1158–1168, November 25, 2009 ª200in the absence of myosin II-driven tension (Figure 7A) (Choi
et al., 2008). As the concentration of SMIFH2 was increased to
20 mM, the percentage of cells that lacked F-actin bundles
increases to 50%, with the rest of the population showing only
thin bundles (Figure 7C). Importantly, all spread cells have an
F-actin-rich lamellipodia near the cell periphery, which is depen-
dent on Arp2/3 complex-mediated actin assembly (Figure 7A,
arrows). Thus, at intermediate SMIFH2 concentrations the fila-
mentous actin organization of cells that remain spread is in the
form of thin F-actin bundles or an isotropic lamellar meshwork.
This is consistent with previous reports that mDia1, in addition
to the Rho effector Rho kinase, is essential to building contractile
stress fibers and the growth of focal complexes (Hotulainen and
Lappalainen, 2006; Riveline et al., 2001; Watanabe et al., 1999).
Changes in F-actin organization and adhesion were not
observed with analog compounds (data not shown).
Impact of SMIFH2 on a Carcinoma Cell Line A549
We treated the carcinoma cell line A549 with a range of SMIFH2
concentrations to determine the effect of SMIFH2 on diverse
cells. A549 cells are exceptionally more tolerant, with an IC50
near 75 mM SMFH2 and a higher dose of SMIFH2 was required
to inhibit growth (Figures S3A and S3B). Treatment of A549
cells for 4 days with 30 mM SMIFH2 increases the percentage9 Elsevier Ltd All rights reserved
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cytokinesis defect.
In contrast to the NIH 3T3 fibroblasts, a majority of A549 cells
treated with 30 mM SMIFH2 remained spread over the course of
an 8 hr time-lapse movie. However, 40% have spherical bleb-
like protrusions that rapidly extended and retracted at the cell
periphery (FiguresS3CandS3D). In10%ofcells, theseprotrusions
were stabilized by adhesion to the external matrix and resulted in
changes incell shape (FiguresS3CandS3D). Immunofluorescence
images revealed regions near the cell periphery with high filamen-
tous actin intensity and numerous small focal complexes that
existed beyond the zone of large focal adhesions (Figure S3E).
Thus, it appears that SMIFH2 treatment induces bleb-like protru-
sionsnear thecell peripherywithout significantly altering the forma-
tion of focal complexes. This is consistent with reports suggesting
that the RhoA pathway and its effector, mDia1, are instrumental in
maintaining cortical integrity to limit protrusive activity (Worthylake
and Burridge, 2003). Such bleb-like protrusions have been
observed in several cell types, but the relative contributions of actin
polymerization and local cortical tension in regulating cellular
protrusions has not been well established (Fackler and Grosse,
2008). These results suggest that reduction in formin-mediated
actin polymerization at the plasma membrane results in local
cortical weakening. In this scenario, the forces for protrusionmight
originate from osmotic pressure-driven changes in membrane
shape rather than from actin polymerization.
Additional work is required to elucidate the mechanism of
differences in drug toxicity between these two cell lines; possible
reasons are changes in expression of different isoforms of
formins or different formin activity due to different levels of the
formin activator RhoA.
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Figure 7. Effect of SMIFH2 on the Actin
Cytoskeleton in NIH 3T3 Fibroblasts
(A) Immunofluorescence of filamentous actin and
paxillin in NIH 3T3 fibroblasts. Cells that remained
spread after SMIFH2 treatment exhibited three
distinct actin cytoskeleton organizations: thick
F-actin bundles, thin F-actin bundles, and no
F-actin bundles. Lamellipodial actin is observed
in all phenotypes and indicated by arrows. Scale
bar, 10 mm.
(B) F-actin bundles observed in (A) are character-
ized by their mean width and the maximum fila-
mentous actin intensity normalized to the local
background.
(C) Percentage of spread cells exhibiting different
actin cytoskeleton phenotypes after 2 hr incuba-
tion with indicated concentrations of SMIFH2
(n > 75 cells for each concentration).
Future Considerations
Analysis of SMIFH2 and the Arp2/3
complex inhibitor CK-666 demonstrates
the usefulness of fission yeast to deter-
mine the specificity of drugs on actin
cytoskeleton processes. Extensive work
is required to determine which specific
actin-modulating proteins are required
for the at least 15 processes in verte-
brates (Chhabra and Higgs, 2007). Fission yeast assembles actin
into just four structures (La Carbona et al., 2006; Marks and
Hyams, 1985). The ease of genetic manipulation and visualiza-
tion of functional GFP-tagged proteins expressed from their
endogenous locus has provided a nearly complete profile of
which evolutionarily conserved actin-binding proteins are
required for each structure in budding and fission yeast (La Car-
bona et al., 2006;Moseley andGoode, 2006). Inhibitor specificity
can be investigated in yeast, and then used to determine which
processes in animals depend on the drug’s target. Yeast has
also been useful for testing the specificity of drugs targeting
other fundamental cellular processes (Lehar et al., 2008; Lopez
et al., 2008).
As a general inhibitor, which targets diverse formin isoforms
with similar potency, SMIFH2may be a useful drug for identifying
cellular processes dependent on formin-mediated actin
assembly in a broad range of experimental systems. However,
it will be important to isolate formin isoform-specific inhibitors
to determine which formin is required for a particular cellular
process. Furthermore, particular formin isoforms are involved
in malignant tumor formation and are highly overexpressed in
a range of cancer cell types (Favaro et al., 2003; Kitzing et al.,
2007; Sarmiento et al., 2008; Zhu et al., 2008). Isoform-specific
inhibitors are likely to be better anti-metastatic tumor drugs
because they may target tumor cells while having less impact
on surrounding healthy tissues.
SIGNIFICANCE
Formins are required to stimulate actin filament assembly
at the correct time and place to drive fundamental cellularChemistry & Biology 16, 1158–1168, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1165
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polarity. Formin inhibitors would be an extremely useful
reagent because most eukaryotic organisms express mul-
tiple formins whose cellular roles have not been determined
and because formins are required for processes deregu-
lated during metastic tumor formation.
We established a simple fluorescent-based in vitro screen
to discover for the first time a general smallmolecular formin
inhibitor that we named SMIFH2 (small molecule inhibitor of
formin FH2 domains). SMIFH2 is a general formin inhibitor
that targets evolutionarily diverse formin isoforms from
budding yeast, fission yeast, nematode worm, and mouse,
with similar 5 to 15 mM half-maximal potency. SMIFH2
inhibits formin at multiple points from preventing both
nucleation and processive barbed end elongation and
decreases formin’s affinity for the barbed end. We verified
that SMIFH2 abolishes formin-dependent actin cytoskeletal
structures in both fission yeast and animal cells. SMIFH2
disrupts formin-dependent actin cables and contractile
rings in fission yeast, but does not target endocytic actin
patches, which are dependent on the other major actin
nucleation factor, Arp2/3 complex. Although it is possible
that SMIFH2 has additional cellular targets, the potency of
analog compounds on formin-mediated actin assembly
in vitro directly correlates with their potency on the fission
yeast formin actin cytoskeleton. In animal cells, SMIFH2
severely disrupts formin-dependent stress fibers and per-
turbs cell division and motility, but does not disrupt Arp2/3
complex-dependent lamellipodia near the cell periphery.
SMIFH2 may be a useful drug to elucidate formin-
dependent processes in a wide range of organisms and cell
types. Future work will focus on elucidating where SMIFH2
binds formin, optimization of SMIFH2 activity, and expan-
sion of the in vitro screen to identify formin isoform-specific
inhibitors.
EXPERIMENTAL PROCEDURES
Compounds and Protein Purification
Compounds were purchased from ChemBridge Corporation: SMIFH2, analog
2, analog 3, analog 4, analog 5, analog 6, and analog 7. Procedures for protein
purification can be found in the Supplemental Experimental Procedures.
Formin Inhibitor Screen
Small molecules were initially screened by a single-point pyrene-fluorescence
assay. In 96 well plates, 1.5 mMMg-ATP-actin (20%pyrene-labeled) and either
10 nM mDia1(FH1FH2) or 20 nM mDia2(FH1FH2) with 1.5 mM mouse profilin
MmPRF1 was assembled in the presence of 960 pools of 8 small molecules
(Chembridge; 12.5 mM final concentration of each small molecule) for 30 min
and read on a Safire2 fluorescent plate reader (Tecan). Positive hits had 50%
or lower fluorescence than control reactions without small molecules. Sixty-
one positive pools were re-screened kinetically by following the time course
of pyrene fluorescence (actin assembly) of 1.5 mM Mg-ATP-actin with 10 nM
mDia1(FH1FH2) or 20 nM mDia1(FH1FH2) and 1.5 mM MmPRF1. Forty-six
positive pools assembled at least 2-fold slower than control reactions without
small molecules. The 368 individual compounds were subsequently screened
against both mDia1 and mDia2 by the single-point assay (42 compounds in-
hibited pyrene fluorescence by at least 50%) and by the kinetic assay (34
compounds slowed the rate of assembly by at least 2-fold). Thirty of the
thirty-four compounds did not inhibit the rate of 1.5 mM actin assembly in
the absence of formin. The final 30 compounds were screened kinetically
over a range of concentrations. Two small molecules, SMIFH2 and analog 2,1166 Chemistry & Biology 16, 1158–1168, November 25, 2009 ª200inhibited formin-mediated actin assembly by at least 50% at a concentration
of 10 mM and were characterized further.
Actin Biochemistry
Procedures for fluorescence spectroscopy, microscopy of fluorescently
labeled actin filaments, and TIRF microscopy can be found in the Supple-
mental Experimental Procedures.
Fission Yeast
Fission yeast strains and microscopy procedures can be found in the Supple-
mental Experimental Procedures.
Tissue Culture
NIH 3T3 Fibroblasts (ATCC) were cultured in high-glucose DMEM (CellGro),
supplemented with 10% FBS (Hyclone), L-glutamine (GIBCO), and Penicillin/
Streptomycin (GIBCO). A549 carcinomic human alveolar basal epithelial cells
were cultured in F12K medium (ATCC), supplemented with 10% FBS (ATCC)
and Penicillin-streptomycin-glutamine solution (ATCC).
Cell Viability
All assays were performed using at least three replicate wells for each
compound concentration tested. Serial dilutions (2- or 3-fold) in DMSO were
performed using a stock solution of SMIFH2 in DMSO. We seeded cells in
96-well white plates at the density of 1000 cells/well (A549 cell line) or 2000
cells/well (3T3 cell line) in 100 ml of the appropriate cell culture media. The cells
were allowed to attach and grow for 24 hr before treatment with serially diluted
SMIFH2 solutions pre-diluted in 25 ml growth media for each data point. After
indicated incubation periods, cell viability was determined with an ATPlite
1step luminescence assay kit (PerkinElmer) according to the manufacturer’s
instructions. Luminescence was analyzed using a Wallac Victor 3 plate reader
(PerkinElmer).
Immunofluorescence
NIH 3T3 Fibroblasts and A549 carcinomic human alveolar basal epithelial cells
were plated onto glass coverslips and allowed to spread for 24 hr. Cells were
fixed at room temperature for 15 min in 4% paraformaldehyde, 0.5% Triton
X-100, and 1.5% bovine serum albumin as a blocking agent. Paxillin antibody
(1:400; Santa Cruz Biotechnology) and Alex Fluor 488 phalloidin (1:400;Molec-
ular Probes) were diluted in 1.5% BSA in phosphate buffered saline (PBS) and
incubated for 1 hr at room temperature. After three washes in PBS, coverslips
were incubated overnight at 4C in Alexa 568-conjugated anti-rabbit (1:400;
Molecular Probes) and were subsequently washed three times in PBS and
mounted in Prolong Gold Antifade reagent (Molecular Probes). Images were
acquired with an inverted Nikon Ti microscope equipped with a cooled CCD
camera (Photometrics, Coolsnap HQ2).
Time-Lapse Imaging
NIH 3T3 Fibroblasts or A549 carcinomic human alveolar basal epithelial cells
were plated onto glass coverslips and allowed to spread for 24 hr. Coverslips
were placed in a sealed chamber with the designated quantity of drug and
20 mM HEPES. Images were collected with a CCD Photometric CoolSnap HQ
Camera at 5min intervals over 8–12 hr with a 203 lens on an automated (Meta-
morph 7.5.4.0; Universal Imaging Corporation) microscope (Nikon Eclipse Ti)
with a heated and motorized stage. For each experiment, ten individual cell
fields were recorded. Phenotypic frequency was measured by scoring inci-
dence of occurrence at each indicated time point. Cells that did not spread
or left the field of view during the length of the experiment were not scored.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
figures, and seven movies and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00333-0.
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